Core Viewpoint - Femasys Inc. has announced a public offering of common stock and warrants, aiming to raise approximately $8.0 million to support its commercial expansion and product development efforts [2][4]. Group 1: Offering Details - The public offering consists of 10,434,586 shares of common stock and pre-funded warrants to purchase up to 11,750,000 shares, with a combined offering price of $0.36 per share and accompanying common warrant [1][2]. - The offering is expected to close on or about August 27, 2025, pending customary closing conditions [2]. Group 2: Use of Proceeds - Femasys plans to utilize the net proceeds from the offering for the expansion of commercial efforts, product development, general corporate purposes, capital expenditures, and working capital [2]. Group 3: Company Overview - Femasys is a biomedical innovator focused on women's health, offering a range of in-office therapeutic and diagnostic products [6]. - The company’s fertility portfolio includes FemaSeed, which is over twice as effective as traditional IUI, and FemVue, a diagnostic tool for fallopian tube assessment [6]. - FemBloc, a non-surgical permanent birth control method, received regulatory approval in Europe and the UK in 2025, with commercialization planned through strategic partnerships [7].

Core Viewpoint - Synergy CHC Corp. has announced a public offering of 1,750,000 shares at a price of $2.50 per share, aiming for gross proceeds of $4.375 million before expenses [1] Group 1: Offering Details - The offering includes a 45-day option for underwriters to purchase an additional 262,500 shares at the same public offering price [1] - The expected closing date for the offering is August 27, 2025, pending customary closing conditions [1] - The company will issue warrants to the underwriter for the purchase of up to 52,500 shares, which can increase to 60,375 shares if the over-allotment is exercised [3] Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for working capital and other general corporate purposes [2] Group 3: Company Overview - Synergy CHC Corp. specializes in consumer health and wellness products, with flagship brands including FOCUSfactor® and Flat Tummy® [7] - FOCUSfactor® is a clinically studied brain health supplement with a 25-year legacy, distributed in major retailers across the U.S., Canada, and the U.K. [7] - The company is experiencing growth and expanding into new markets, with recent retail successes expected to drive gains in late 2025 [7]

Core Viewpoint - Unitil Corporation has announced a public offering of 1,393,355 shares of common stock priced at $46.65 per share, expected to close on August 18, 2025 [1]. Group 1: Offering Details - The underwriters have an option to purchase an additional 209,003 shares at the public offering price, minus underwriting discounts and commissions [2]. - The net proceeds from the offering will be used for equity capital contributions to regulated utility subsidiaries, repayment of outstanding indebtedness, and general corporate purposes [3]. - Wells Fargo Securities, LLC and Scotia Capital (USA) Inc. are acting as active bookrunners for the offering, with Janney Montgomery Scott LLC as a bookrunner [4]. Group 2: Company Overview - Unitil Corporation provides energy services, delivering electricity and natural gas in New England, serving approximately 109,400 electric customers and 97,600 natural gas customers [6].

Market Trends & Investor Sentiment - Retail investors are increasingly active in the stock market, favoring individual stocks over ETFs, with mega-cap tech and AI-related stocks being popular choices [2][4][8][11][13] - Investopedia's survey indicates strong positive sentiment among self-directed investors, driven by record highs and expectations of deregulation and rate cuts [5][6][7][17][18][36] - Investors show a preference for holding onto their current stock investments, particularly in large-cap tech, with Nvidia, Palantir, Microsoft, Apple, and Amazon being top choices for the next 10 years [9][10] - A survey reveals that if investors had an extra 10,000 (unit unspecified), 22% would invest it in individual stocks [4] Economic Indicators & Monetary Policy - The Producer Price Index (PPI) showed higher than expected inflation, particularly in services, raising concerns for the Federal Reserve [1][24][25] - Despite inflation data, markets largely expect the Federal Reserve to cut interest rates by 25 basis points in September [26][27] - Crypto markets experienced a downturn with Bitcoin down 4% after hitting an all-time high, but overall, crypto has seen significant gains year-to-date, supported by institutional interest and a friendlier regulatory environment [30][31][32] Fannie Mae & Freddie Mac Potential IPO - The Trump administration is considering an IPO for Fannie Mae and Freddie Mac, which could raise approximately 30 billion (unit unspecified) for taxpayers and unwind their 2008 conservatorship [3][37][38] - An IPO would introduce new shares and capital, potentially leading to a major exchange listing, but the government's backing is likely to continue unless Congress intervenes [45][46] - The value of the two mortgage giants could exceed 500 billion (unit unspecified) combined if the IPO proceeds [45] - Existing shareholders are expected to face massive dilution, with the federal government potentially owning over 90% [44][45]

Company Overview - BioSig Technologies, Inc. recently merged with Streamex Exchange Corporation, enhancing its market position in the gold tokenization sector [1][5] - BioSig is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6][7] Public Offering Details - The company announced a public offering of 3,852,149 shares of common stock at a price of $3.90 per share, with expected gross proceeds of approximately $15,023,381.10 [1] - The offering is set to close on or around August 15, 2025, subject to customary closing conditions [1] Use of Proceeds - The net proceeds from the offering will be utilized for purchasing gold bullion, working capital, and general corporate purposes [1] Underwriters - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Regulatory Compliance - The offering is made under a shelf registration statement declared effective by the SEC on December 17, 2024, with a final prospectus supplement to be filed [3]

Core Viewpoint - BioSig Technologies, Inc. has announced its intention to offer shares of common stock through an underwritten public offering, following its recent merger with Streamex Exchange Corporation [1] Group 1: Offering Details - The offering will include shares of common stock or pre-funded warrants, with the completion subject to market conditions [1] - The net proceeds from the offering are intended for purchasing gold bullion, working capital, and general corporate purposes [1] - Clear Street and Needham & Company are acting as joint book-running managers for the offering [2] Group 2: Regulatory Information - The offering is made pursuant to a shelf registration statement on Form S-3, declared effective by the SEC on December 17, 2024 [3] - A preliminary prospectus supplement will be filed with the SEC, and interested parties are encouraged to read the documents for more information [3] Group 3: Company Background - BioSig Technologies is a medical device technology company specializing in advanced digital signal processing technology for electrophysiology [6] - The PURE EP™ Platform developed by the company allows for real-time acquisition of raw signal data, enhancing procedural success in ablation treatments [7] - Streamex, a wholly owned subsidiary of BioSig, focuses on gold tokenization and building infrastructure for the gold market [5]

Core Points - Ondas Holdings Inc announced a proposed public offering of its common stock, with the size of the offering not disclosed, and plans to grant underwriters a 30-day option to purchase additional shares [1][2] - The net proceeds from the offering are expected to be used for working capital, general corporate purposes, and potential strategic transactions [2] - Ondas reported second-quarter revenue of $6.27 million, exceeding estimates of $4.97 million, and a quarterly loss of eight cents per share, better than the estimated loss of 10 cents per share [3] - The company ended the quarter with approximately $68.55 million in cash, cash equivalents, and restricted cash [3] - Ondas stated that it retired the remaining balance of its convertible notes in July, enhancing its financial position, and anticipates a record backlog and clear revenue visibility into 2026 [4] - Following the announcement, Ondas shares fell by 13.05% in after-hours trading, reaching $3.73 [5]

Company Overview - SPX Technologies, Inc. is a diversified global supplier of highly engineered products and technologies, holding leadership positions in the HVAC and detection and measurement markets [5] - The company is based in Charlotte, North Carolina, and employs over 4,300 individuals across more than 16 countries [5] - SPX is publicly traded on the New York Stock Exchange under the ticker symbol "SPXC" [5] Public Offering Details - SPX announced its intention to offer and sell $500 million of shares of its common stock in an underwritten public offering [1] - The company plans to grant underwriters a 30-day option to purchase up to an additional $75 million of shares [1] - The offering is subject to market conditions, and there is no assurance regarding the completion or terms of the offering [1] Underwriters - BofA Securities, J.P. Morgan, and Wells Fargo Securities are acting as joint book-running managers for the proposed offering [2] - TD Cowen and Truist Securities are also involved as book-running managers for the offering [2] Regulatory Compliance - The shares are being offered pursuant to an effective automatic shelf registration statement previously filed with the U.S. Securities and Exchange Commission (SEC) [3] - A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the offering [3]

Core Viewpoint - BioVie Inc. has announced a public offering of 6,000,000 units at a price of $2.00 per unit, aiming to raise approximately $12 million for working capital and general corporate purposes [1][2]. Group 1: Offering Details - Each unit consists of one share of common stock and one warrant, with pre-funded units available [1]. - The gross proceeds from the offering are expected to be around $12 million before deducting underwriting discounts and commissions [1]. - The warrants will be immediately exercisable at an exercise price of $2.50 per share and will expire five years from issuance [1]. - The underwriter has a 45-day option to purchase up to an additional 900,000 shares or warrants to cover over-allotments [1]. Group 2: Company Overview - BioVie Inc. is a clinical-stage company focused on developing innovative drug therapies for chronic debilitating conditions, including liver disease and neurological disorders [5]. - The company's drug candidate bezisterim targets neuroinflammation and insulin resistance, which are significant factors in Alzheimer's and Parkinson's diseases [5]. - BioVie’s orphan drug candidate BIV201 is under evaluation for treating liver cirrhosis and ascites, with FDA Fast Track status [5].

Group 1 - Sana Biotechnology, Inc. has priced its underwritten public offering of 20,895,522 shares of common stock at $3.35 per share and pre-funded warrants to purchase 1,492,537 shares at $3.3499 per warrant [1] - The gross proceeds from the offering are expected to be approximately $75.0 million before deducting underwriting discounts and commissions [1] - The offering is expected to close on or about August 8, 2025, subject to customary closing conditions [1] Group 2 - Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering [2] - The offering is being made pursuant to a Registration Statement on Form S-3, which has been declared effective by the SEC [3] - A final prospectus supplement and accompanying prospectus will be filed with the SEC [3] Group 3 - Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients [5] - The company has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA [5]